What are the results of a repeat echocardiogram (echo) post Transcatheter Aortic Valve Replacement (TAVR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A repeat echocardiogram after transcatheter aortic valve replacement (TAVR) should be performed at 30 days post-procedure and then annually thereafter to monitor for complications and guide medical therapy. This recommendation is based on the 2017 ACC expert consensus decision pathway for TAVR in the management of adults with aortic stenosis, which emphasizes the importance of echocardiography in monitoring transcatheter valve function and detecting potential complications 1. The first post-discharge echo at 30 days is crucial to establish a new baseline for valve function and to detect any early complications, such as paravalvular leaks or valve thrombosis.

Key elements to be assessed during the repeat echocardiogram include:

  • Valve hemodynamics (mean gradient, effective orifice area)
  • Evaluation of regurgitation
  • Assessment of left and right ventricular function
  • Evaluation of mitral valve anatomy and function
  • Estimation of pulmonary pressures
  • Evaluation of the right ventricle

More frequent echocardiograms may be necessary if there are concerning symptoms such as shortness of breath, chest pain, syncope, or if there were complications during the initial procedure 1. The long-term durability of transcatheter bioprosthetic valves is not yet known, so annual evaluation for regurgitation, stenosis, and leaflet calcification or thrombosis is appropriate 1.

The monitoring schedule is essential because early detection of valve dysfunction allows for timely intervention, potentially preventing more serious complications and improving long-term outcomes after TAVR. Additionally, periodic echocardiography allows optimization of medical therapy for concurrent cardiac conditions, such as left ventricular dysfunction, coronary disease, and pulmonary hypertension 1.

From the Research

Post-TAVR Echocardiogram Results

The results of a repeat echocardiogram post Transcatheter Aortic Valve Replacement (TAVR) can be summarized as follows:

  • Echocardiography is used to assess prosthetic valve function, left ventricular functional recovery, and the impact of the procedure on associated conditions such as mitral regurgitation, pulmonary hypertension, or tricuspid regurgitation 2
  • Post-TAVR echo assessment should allow prompt recognition of early complications and the severity of para-valvular leaks 2
  • Device landing zone calcification predicts significant paravalvular regurgitation after TAVR, which can be evaluated by real-time three-dimensional transesophageal echocardiography 3
  • Echocardiographic follow-up after TAVR is crucial to detect long-term complications such as infective endocarditis, thrombosis, and to assess the structural and functional status of bioprostheses used in TAVR 4

Parameters Assessed by Echocardiogram

The following parameters are assessed by echocardiogram post-TAVR:

  • Left ventricular ejection fraction (LVEF) 5, 6
  • Left ventricular mass and wall thickness 5
  • Global longitudinal strain (GLS) 5
  • Paravalvular leak (PVL) 5
  • Mean gradient (MG) 6
  • Transaortic flow/Stroke Volume Index (SVI) 6
  • Dimensional index (DI) 6
  • Aortic valve area (AVA) 6
  • Maximum velocity (V max) 6

Impact of Paravalvular Leak on Left Ventricular Remodeling

Paravalvular leak (PVL) can impede reverse left ventricular remodeling but not global longitudinal strain improvement 1-year after TAVR 5

  • Patients without PVL had significant LVEF, wall thickness, and LV mass improvement compared to patients with PVL 5
  • Diastolic function worsened in patients with PVL 5

Predictors of Long-Term Outcomes

The following parameters are associated with long-term outcomes after TAVR:

  • LVEF less than 35% is associated with higher rate of 1-year mortality 6
  • Low LVEF <35% remains the strongest parameter associated with 1-year mortality after TAVR 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.